Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
about
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell diseaseHeme-mediated cell activation: the inflammatory puzzle of sickle cell anemia.Hydroxyurea in sickle cell disease: drug review.Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activationIntercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium.How I use hydroxyurea to treat young patients with sickle cell anemia.Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell diseaseDifferential modulation of adhesion molecule expression by hydroxycarbamide in human endothelial cells from the micro- and macrocirculation: potential implications in sickle cell disease vasoocclusive events.Erythroid Adhesion Molecules in Sickle Cell Anaemia Infants: Insights Into Early PathophysiologyExamination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia.Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children.Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy.Current strategies for the management of children with sickle cell disease.Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease.The trials and hopes for drug development in sickle cell disease.Nongenomic actions of thyroid hormone.The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease PatientsBiomechanics and biorheology of red blood cells in sickle cell anemia.The role of rs1984112_G at CD36 gene in increasing reticulocyte level among sickle cell disease patients.Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia.Effects of hydroxyurea on monoclonal antibody production induced by anti-mIgG and LPS stimulation on murine B cell hybridomas.Treating sickle cell anaemia with hydroxycarbamide.Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.Genetic variation in CD36, HBA, NOS3 and VCAM1 is associated with chronic haemolysis level in sickle cell anaemia: a longitudinal study.Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia.Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera.CD47Flow cytometry analyses reveal association between Lu/BCAM adhesion molecule and osteonecrosis in sickle cell disease
P2860
Q24627155-861D26E8-976D-4532-9B18-841935DD7428Q27303155-EFB6D128-77C8-4142-A07C-2BAFD3BB2806Q28828635-7A956021-CAD1-4579-97B9-CDD0104FBD66Q33365378-503FB318-7C50-4F48-9C9F-A256D4B414D6Q33619642-25802E9E-C8C4-450C-953F-02A89CDAA3B5Q33676406-9E400D2C-3C8B-4DD6-8371-0B06D48BB00FQ33829064-57BC0701-116C-492D-B9B4-DE3DADCDFC00Q33985120-8718779F-184A-47A8-9C65-555B457A2BE4Q34255075-EEACAE27-5A04-4217-B421-F73EAAB8D36DQ34750534-2F84042A-DC83-41D4-9E6E-EC041CA905AFQ35797724-FC2D9A42-BD32-4079-8173-381D82C7010DQ35999807-6B069AB7-CA36-4498-B5D5-C00A5E9921DDQ36892578-6BA4FD83-1006-4B19-B481-ADB58138514DQ37107206-241A04E2-7A42-4E31-A088-6E0D43CFB58FQ37700189-30736BC3-0A88-45A8-8847-7077D4EF354FQ37810082-81DDA84E-D4C6-4101-95DA-D717BFFDFFD1Q38177946-66239787-4662-4A30-BD03-0DFE080D32A8Q38540335-F22FEA2D-7D3A-48E4-B693-0983519D64DAQ38669510-D2200CA5-04F8-4327-AFB0-F8D66BBA23FFQ38726145-07B2D77D-1B2A-45E7-83FD-9E5EC1F2242DQ39017039-1E840148-3000-49A2-AB42-0A6906D757B3Q39116002-F53FAC80-103A-4E2F-AB18-92374A654DE6Q41320530-EE4533FE-2D9B-4044-85D9-8FBF065FBC46Q42432488-C5BED31A-FB1E-42C9-8266-1ADDDEE76DB5Q44076004-4B348703-F084-4BE8-AFC3-8076EA021844Q46520558-44A1D575-121F-4D7D-8384-B9CD1B4310A0Q48919012-8989D26E-ED1A-4636-8419-CC5FF76ACB67Q49952941-F9FA728E-5F1D-44D5-B934-587AE3025988Q50201524-28839F7A-F401-4763-838C-D542A2847467Q50230368-439DCBCD-A19F-4CC4-890E-40E6B79F2936Q50547239-0BFFC531-384D-44C3-82A4-ED58FADAF223Q51707094-D173D33D-ECD8-495B-B695-0B6ACF29CFACQ52620954-369A177E-CC97-41BD-9CD1-75DD0204D2E2Q56592275-31F294ED-6564-4B2B-A22F-A069B5F77BE8Q57208548-7CE5E8FD-8180-44F6-A7E4-6BB48543F208
P2860
Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@en
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@nl
type
label
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@en
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@nl
prefLabel
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@en
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@nl
P2093
P50
P356
P1433
P1476
Modulation of erythroid adhesi ...... dren with sickle cell disease.
@en
P2093
Corinne Alberti
Jean-Pierre Cartron
Malika Benkerrou
Marie-Hélène Odièvre
Rolande Ducrocq
Viviane Bony
P304
P356
10.3324/HAEMATOL.12070
P577
2008-03-05T00:00:00Z